Compare AMRC & MNKD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AMRC | MNKD |
|---|---|---|
| Founded | 2000 | 1991 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Engineering & Construction | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.2B |
| IPO Year | 2010 | 2004 |
| Metric | AMRC | MNKD |
|---|---|---|
| Price | $25.65 | $4.11 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 8 | 8 |
| Target Price | ★ $37.88 | $8.69 |
| AVG Volume (30 Days) | 640.3K | ★ 4.8M |
| Earning Date | 05-04-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,769,928,000.00 | $348,966,000.00 |
| Revenue This Year | $10.71 | $35.81 |
| Revenue Next Year | $9.07 | $11.89 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 22.23 |
| 52 Week Low | $18.38 | $2.23 |
| 52 Week High | $44.93 | $6.51 |
| Indicator | AMRC | MNKD |
|---|---|---|
| Relative Strength Index (RSI) | 54.05 | 45.88 |
| Support Level | $24.73 | $3.78 |
| Resistance Level | $33.03 | $3.94 |
| Average True Range (ATR) | 1.86 | 0.22 |
| MACD | 0.71 | -0.02 |
| Stochastic Oscillator | 52.93 | 20.18 |
Ameresco Inc is an energy infrastructure solutions provider dedicated to helping customers reduce costs, enhance resilience, and decarbonize to net zero in the energy transition. Its comprehensive portfolio includes implementing smart energy efficiency solutions, upgrading aging infrastructure, and developing, constructing, and operating distributed energy resources. Its solutions range from upgrades to facility's energy infrastructure to the development, construction and operation of renewable energy plants combined with tailored financial solutions. Its segments include North America Regions, U.S. Federal, Renewable Fuels, Europe, and Others. The majority of the revenue is derived from North America Regions segment.
MannKind Corp is a biopharmaceutical company focused on the development and commercialization of patient-centric therapies that address serious unmet medical needs for those living with cardiometabolic and orphan lung diseases. The Company is currently commercializing three products: Afrezza (insulin human) Inhalation Powder, an ultra rapid-acting inhaled insulin indicated to improve glycemic control in adults with diabetes; Furoscix (furosemide injection), to treat fluid buildup in patients with chronic heart failure or chronic kidney disease; and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults that require insulin.